Lumos Pharma Stock Z Score
| LUMO Stock | USD 4.33 0.01 0.23% |
Lumos | Z Score |
Lumos Pharma Company Z Score Analysis
Lumos Pharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Lumos Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Lumos Pharma is extremely important. It helps to project a fair market value of Lumos Stock properly, considering its historical fundamentals such as Z Score. Since Lumos Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lumos Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lumos Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Lumos Pharma has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Lumos Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in z score category among its peers.
Lumos Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lumos Pharma from analyzing Lumos Pharma's financial statements. These drivers represent accounts that assess Lumos Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lumos Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 366.1K | 242.0M | 57.8M | 30.2M | 25.9M | 39.6M | |
| Enterprise Value | (89.0M) | 143.7M | (36.5M) | (25.5M) | (8.6M) | (9.0M) |
Lumos Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lumos Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lumos Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Lumos Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Lumos Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lumos Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lumos Pharma's value.| Shares | Millennium Management Llc | 2024-06-30 | 37 K | Bridgeway Capital Management, Llc | 2024-06-30 | 27.6 K | Marquette Asset Management Inc. | 2024-06-30 | 25.8 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 25.3 K | Envestnet Asset Management Inc | 2024-06-30 | 19.5 K | Two Sigma Investments Llc | 2024-06-30 | 18.9 K | Citadel Advisors Llc | 2024-06-30 | 18.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 11.9 K | Wealth Advisors Of Iowa, Llc | 2024-09-30 | 11.7 K | Private Advisor Group, Llc | 2024-09-30 | 744.5 K | Wells Fargo & Co | 2024-06-30 | 415 K |
Lumos Fundamentals
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 24.1 M | ||||
| Shares Outstanding | 8.65 M | ||||
| Shares Owned By Insiders | 32.69 % | ||||
| Shares Owned By Institutions | 24.27 % | ||||
| Number Of Shares Shorted | 86.38 K | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 7.62 X | ||||
| Price To Sales | 16.98 X | ||||
| Revenue | 2.05 M | ||||
| Gross Profit | 1.52 M | ||||
| EBITDA | (36.57 M) | ||||
| Net Income | (34.03 M) | ||||
| Cash And Equivalents | 79.51 M | ||||
| Cash Per Share | 9.49 X | ||||
| Total Debt | 585 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.59 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (31.09 M) | ||||
| Short Ratio | 0.92 X | ||||
| Earnings Per Share | (4.28) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 4.25 | ||||
| Number Of Employees | 30 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 37.45 M | ||||
| Total Asset | 40.64 M | ||||
| Retained Earnings | (161.52 M) | ||||
| Working Capital | 33.01 M | ||||
| Current Asset | 115.78 M | ||||
| Current Liabilities | 14.4 M | ||||
| Net Asset | 40.64 M |
About Lumos Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lumos Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lumos Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lumos Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock: Check out Lumos Pharma Piotroski F Score and Lumos Pharma Valuation analysis. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.